Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AOBO finally starting to move, after AMEX announcement (on what looks like record or near-record volume pace). FYI, also may want to check out company's financials -- look pretty terrific, to my relatively-untrained eye...
AOBO finally starting to move, after AMEX announcement (on what looks like record or near-record volume pace). FYI, also may want to check out company's financials -- look pretty terrific, to my relatively-untrained eye...
AOBO finally starting to move, after AMEX announcement (on what looks like record or near-record volume pace). FYI, also may want to check out company's financials -- look pretty terrific, to my relatively-untrained eye...
AOBO approved for AMEX listing (FYI, same kind of news LENF got yesterday, sending it up nearly 100% -- and it's still going...)
========================
- Business Wire, July 12 -
American Oriental Bioengineering's Common Stock Approved for Listing on the American Stock Exchange
American Oriental Bioengineering, Inc. (OTCBB: AOBO), a rapidly growing Chinese company which produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that its common stock has been approved for listing on the American Stock Exchange (AMEX). The company anticipates that its common stock will commence trading on AMEX on July 18, 2005 under the ticker symbol AOB.
AMEX's approval for listing is contingent upon the company being in compliance with all applicable listing standards on the date it begins trading on the exchange, and may be rescinded if the company is not in compliance with such standards.
"We believe that the listing of our company's common stock on AMEX represents recognition from the investment community of the rapid growth and increasing profitability we are experiencing," said Tony (Shujun) Liu, the Company's Chief Executive Officer. "A listing on AMEX should allow us to further increase awareness of our company among the investment community and enable a larger range of investors to own our stock. This listing is a reflection of the contributions we have received from our employees, customers and shareholders who have made this possible."
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. (AOBO) is a leading Chinese biotechnology company that uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. The Company also produces Cease-Enuresis Soft Gel, the only Chinese FDA-approved first grade, prescription medicine that is specially formulated to help alleviate bed-wetting and incontinence. The Company is a leading producer of products in both the nutraceuticals and pharmaceuticals areas in China. For more information, visit http://www.bioaobo.com.
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks discussed from time to time in reports filed by the company with the Securities and Exchange Commission. . All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. The company cannot guarantee its future results, levels of activity, performance or achievements. In addition, the company disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
American Oriental Bioengineering, Inc.
Lily Li, 917-838-0689 (U.S.) or +86-451-86688139 (China)
aobo@bioaobo.com
or
Investors:
CEOcast, Inc. for American Oriental Bioengineering
Ed Lewis, 212-732-4300
elewis@ceocast.com
AOBO approved for AMEX listing (same kind of news LENF got yesterday, sending it up nearly 100% -- and it's still going...)
========================
- Business Wire, July 12 -
American Oriental Bioengineering's Common Stock Approved for Listing on the American Stock Exchange
American Oriental Bioengineering, Inc. (OTCBB: AOBO), a rapidly growing Chinese company which produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that its common stock has been approved for listing on the American Stock Exchange (AMEX). The company anticipates that its common stock will commence trading on AMEX on July 18, 2005 under the ticker symbol AOB.
AMEX's approval for listing is contingent upon the company being in compliance with all applicable listing standards on the date it begins trading on the exchange, and may be rescinded if the company is not in compliance with such standards.
"We believe that the listing of our company's common stock on AMEX represents recognition from the investment community of the rapid growth and increasing profitability we are experiencing," said Tony (Shujun) Liu, the Company's Chief Executive Officer. "A listing on AMEX should allow us to further increase awareness of our company among the investment community and enable a larger range of investors to own our stock. This listing is a reflection of the contributions we have received from our employees, customers and shareholders who have made this possible."
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. (AOBO) is a leading Chinese biotechnology company that uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. The Company also produces Cease-Enuresis Soft Gel, the only Chinese FDA-approved first grade, prescription medicine that is specially formulated to help alleviate bed-wetting and incontinence. The Company is a leading producer of products in both the nutraceuticals and pharmaceuticals areas in China. For more information, visit http://www.bioaobo.com.
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks discussed from time to time in reports filed by the company with the Securities and Exchange Commission. . All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. The company cannot guarantee its future results, levels of activity, performance or achievements. In addition, the company disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
American Oriental Bioengineering, Inc.
Lily Li, 917-838-0689 (U.S.) or +86-451-86688139 (China)
aobo@bioaobo.com
or
Investors:
CEOcast, Inc. for American Oriental Bioengineering
Ed Lewis, 212-732-4300
elewis@ceocast.com
LENF approaching 4 bucks...
LENF approaching 4 bucks...
LENF still going...
LENF still going... (FWIW)
LENF at new HOD...
LENF at new HOD...
LENF news, approved for AMEX...
(BSNS WIRE) American Stock Exchange Approves Law Enforcement Associates Stock Listing and Assigns ``Aid'' as Its Trading Symbol American Stock Exchange Approves Law Enforcement Associates Stock Listing and Assigns ``Aid'' as Its Trading Symbol
Business Editors
YOUNGSVILLE, N.C.--(BUSINESS WIRE)--July 11, 2005--
Law Enforcement Associates Corporation (OTCBB: LENF), a
surveillance and security technology company, announced today that the
American Stock Exchange has approved the Company's application for the
listing of its common stock. The Company anticipates that its stock
will commence trading on the AMEX on Friday, July 15, 2005 with "AID"
as its trading symbol. The AMEX's approval is contingent upon the
Company's being in compliance with all applicable listing standards on
the date the Company's stock begins trading on the AMEX and may be
rescinded if the Company is not in compliance with such standards.
Paul Feldman, President of the Company comments, "We are very
excited that the American Stock Exchange has approved the listing of
our common stock. Management has worked very hard on the application
and we believe that becoming listed on the American Stock Exchange
will benefit our stockholders as our stock is now listed on recognized
exchange."
About Law Enforcement Associates Corporation
Law Enforcement Associates, Inc. (LENF.OB), headquartered in
Youngsville, N.C., manufactures and markets a diverse line of
undercover surveillance products including a complete line of audio
surveillance equipment and Homeland Security Products. LEA currently
markets to the Military, law enforcement, security and corrections
personnel throughout the world, as well as governmental agencies,
multinational corporations and non-governmental organizations. LEA has
a history of enhancing security at major events including the Summer
Olympics, Democratic National Convention, Super Bowl, Winter Olympic
Games and Centennial First Flight Celebration and most recently a key
security element for the 2005 US Open Golf Championship. The company's
technology is also used as a prevention and detection solution at
military bases, nuclear facilities, embassies, government
installations, oil refineries, and United Nations and NATO locations
throughout the world.
LENF news, approved for AMEX...
(BSNS WIRE) American Stock Exchange Approves Law Enforcement Associates Stock Listing and Assigns ``Aid'' as Its Trading Symbol American Stock Exchange Approves Law Enforcement Associates Stock Listing and Assigns ``Aid'' as Its Trading Symbol
Business Editors
YOUNGSVILLE, N.C.--(BUSINESS WIRE)--July 11, 2005--
Law Enforcement Associates Corporation (OTCBB: LENF), a
surveillance and security technology company, announced today that the
American Stock Exchange has approved the Company's application for the
listing of its common stock. The Company anticipates that its stock
will commence trading on the AMEX on Friday, July 15, 2005 with "AID"
as its trading symbol. The AMEX's approval is contingent upon the
Company's being in compliance with all applicable listing standards on
the date the Company's stock begins trading on the AMEX and may be
rescinded if the Company is not in compliance with such standards.
Paul Feldman, President of the Company comments, "We are very
excited that the American Stock Exchange has approved the listing of
our common stock. Management has worked very hard on the application
and we believe that becoming listed on the American Stock Exchange
will benefit our stockholders as our stock is now listed on recognized
exchange."
About Law Enforcement Associates Corporation
Law Enforcement Associates, Inc. (LENF.OB), headquartered in
Youngsville, N.C., manufactures and markets a diverse line of
undercover surveillance products including a complete line of audio
surveillance equipment and Homeland Security Products. LEA currently
markets to the Military, law enforcement, security and corrections
personnel throughout the world, as well as governmental agencies,
multinational corporations and non-governmental organizations. LEA has
a history of enhancing security at major events including the Summer
Olympics, Democratic National Convention, Super Bowl, Winter Olympic
Games and Centennial First Flight Celebration and most recently a key
security element for the 2005 US Open Golf Championship. The company's
technology is also used as a prevention and detection solution at
military bases, nuclear facilities, embassies, government
installations, oil refineries, and United Nations and NATO locations
throughout the world.
Yes, chat problems also. Not sure if Riv has changed the membership setup, or what...
Please disregard earlier chatroom question -- working okay now, for whatever reason...
Anyone having chatroom problems this morning? My browser won't even connect to the "1stdaytrader" homepage, to let me start the login process. Page just goes blank, and says "Done" on the taskbar. Thanks for any advice...
FWIW, AUTQ popping now from nasty low of yesterday. At .014 now...
Thanks, excel just pointed that out to me (and a few others, who were likewise confused). Appreciate all the help, and will be checking chat again in morning (will be reading-in as much as possible, even if my "real job" prevents me from doing much active posting). Have a good night, and here's hoping everyone has a good day tomorrow...
globe
Okay, I'm in. Suddenly realized that the problem apparently was that I'd been trying to access chat using my Netscape browser, instead of IE -- and that I'd found that when I originally joined, Netscape didn't work for some reason. It still doesn't, but not that my memory's been jogged I've switched to IE and all seems well...
Still one problem, don't see chatroom border to allow me to maximize screen as in the past. But I'll try troubleshooting that one within chat itself...
Thanks again for your patience -- and just out of curiosity, has anyone ever managed to get in using Netscape instead?...
Looking forward to tomorrow...
globe
Okay, one step closer. I've now gotten to the page saying "member chat area," using the second password I was sent. But if I now click on the "Chatroom" button at the bottom of that page, I get a "URL Not Found" prompt (a "404" error).
Do I need to re-install the plugin first, even though I already have it from before? Or do I need to do something else, to actually enter the chatroom?
Sorry to sound like a dufus, but I don't mind coming off dumb as long as I get set-up to enter chat in the morning. So thanks for the hand-holding...
Jonathan...
Sorry, just now got home and tried to follow instructions for re-registering for IDT/chat -- and like others have indicated before, I'm having trouble getting in. First registered with all the personal info, then logged trying two DIFFERENT passwords I was e-mailed (one I got the first time, and another I got when I said I'd forgotten it and needed a reminder). So far, with either one I just get an "access denied" prompt on the Members Login Page.
Not sure if I screwed something up, or if it's just "birth pangs" for the new site. Any suggestions? Thanks in advance...
globe
FYI: ERHC deal is not with PIOL, but PXD (similar company names)...
OK, thanks...
Rivet: Is chatroom down? Got knocked out, and when I try to get back in I'm the only one listed as being there...
Anybody else here been bumped out of chatroom? Seems to be acting up...
warrior: thanks for your reply also. Suggest you try same thing I did. Go to just "switchfoottrades.com" -- then click on chatroom link at bottom and log in manually. Hope that works for you. And no, I wasn't in last night's chat -- can't usually make those hours (even have trouble monitoring/contributing to the room during normal market hours, because of other commitments). But glad it was a good session...
Thanks, Mosby -- finally got in by going first to homepage, rather than straight to chat URL as usual. Then had to log in with entire member-name as well as password. Don't know why the problem, but at least I'm in now...
Anybody else having chatroom problems again today? (I keep getting "Page Not Found" message)... TIA
Re MyTrack: My L-2 seems okay (for OTCBB and everything else), as far as I can tell. I'm currently on server 33-1. But I've also had some problems in the past with bad feeds, and have had to log out and back in to straighten things out. In fact I'm not sure how to manually choose a server -- is there a way?...
FWIW: Today's volume in ICRA is already way-above any daily total I can find in the stock's history -- even excluding one gigantic single trade of more than six-million shares, at the day's low of .25...
Really have no idea what to make of it, because the trading today has been all over the map. But probably worth keeping an eye on.
Personally, I never understood the reason for the recent big drop anyway because the June 7th PR sounded GOOD to me (with the FDA taking the unusual step of asking the company to SPEED-UP its clinical trials). But maybe I just didn't grasp it right, since others seem to have reacted to it negatively instead...
FWIW: Today's volume in ICRA is already way-above any daily total I can find in the stock's history -- even excluding one gigantic single trade of more than six-million shares, at the day's low of .25...
Really have no idea what to make of it, because the trading today has been all over the map. But probably worth keeping an eye on.
Personally, I never understood the reason for the recent big drop anyway because the June 7th PR sounded GOOD to me (with the FDA taking the unusual step of asking the company to SPEED-UP its clinical trials). But maybe I just didn't grasp it right, since others seem to have reacted to it negatively instead...
Update -- I finally got in...
Jonathan -- got your PM's (thanks), have tried re-registering with the new username you mentioned (which is not the same as yesterday) and yesterday's password. But still no luck, still getting told that either the username or password are invalid. Weird...
Jonathan: In my case, at least, the cookies are fully-baked but I still can't get in. Keep getting told that either the username or password (same ones used yesterday) are invalid..
I sent PM on this earlier (to excel), but just FYI: I haven't been able to log into Switchfoot either this morning, had no problems yesterday...
LOOK-ing pretty good (financial data released)...
===================================================
LookSmart Reports First Quarter Revenues of $27.8 Million; Raises Full Year Guidance
Thursday April 29, 4:15 pm ET
SAN FRANCISCO, April 29 /PRNewswire-FirstCall/ -- LookSmart (Nasdaq: LOOK - News; ASX: LOK - News), a leader in Internet search, today announced financial results for the quarter ended March 31, 2004. In a separate release today, LookSmart also announced the acquisition of the business and assets of Net Nanny(TM), a privately held leader in the consumer online filtering sector.
ADVERTISEMENT
"LookSmart's focus on providing high performance traffic at a reasonable price is proving to be popular with advertisers and distribution partners, resulting in first quarter results ahead of our expectations," said Damian Smith, LookSmart's chief executive officer. "Our core ongoing business, which excludes our international operations and contributions from MSN, grew over 30% sequentially. With our focused cost reductions substantially complete, healthy growth in our distribution network and contributions from new initiatives such as our acquisition of Net Nanny, we are pleased to significantly increase our guidance for the year. Our increased full year guidance, which reflects greatly reduced revenue from MSN as compared to the first quarter, suggests strong growth within our ongoing distribution network as we continue to add and leverage new sources of high performance search traffic."
LookSmart reported first quarter 2004 revenue of $27.8 million, ahead of its prior guidance of $21 million to $23 million. This includes revenue from MSN domestically of $8 million and international revenue of $4 million. First quarter revenue compares to $33.4 million in the first quarter of 2003, which included domestic revenue from MSN of $22 million and international revenue of $2 million; and $44.1 million in the preceding quarter, which included domestic revenue from MSN of $25 million and international revenue of $6 million.
As of March 31, 2004, total cash and short-term investments were $71.6 million, an increase of $1.6 million from the end of the previous quarter.
GAAP net loss for first quarter 2004 was $7.1 million, or $0.07 per share, which includes reductions in net income of $3.8 million related to restructuring charges and $27,000 due to stock compensation from variable stock options. This compares to net income in the first quarter 2003 of $1.1 million, or $0.01 per share, which included a net gain of $0.2 million related to the purchase of the BT LookSmart joint venture entities and a $0.9 million charge due to variable accounting for repriced stock options.
LookSmart's adjusted net loss, which excludes $27,000 of stock compensation from variable stock options and includes a restructuring charge of $3.8 million, was $7.1 million, or $0.07 per diluted share for the quarter, ahead of the Company's guidance for a net loss of $10 million to $12 million including restructuring charges of approximately $4 million to $5 million. This compares to adjusted net income of $2.0 million, or $0.02 per diluted share in the year-ago period, which excludes $0.9 million of stock compensation from variable stock options.
Adjusted net income/loss is not in accordance with, or an alternative to, GAAP financial measures and may be different from pro forma measures used by other companies. The Company has provided a clear reconciliation between GAAP net income/loss and adjusted net income/loss and has presented the information previously reported together with the financial statements attached to this earnings release. The Company does not provide all of its guidance on a GAAP basis because information relating to the variable accounting for repriced stock options is not accessible on a forward-looking basis and its probable significance is not determinable.
Financial Outlook
For the second quarter ending June 30, 2004, total revenue is expected to be $18 million to $20 million, including approximately $1 million from domestic MSN and $2 million from international operations. In the second and third quarters of 2004, we expect to report results from international operations as discontinued operations. Adjusted net loss for the second quarter is expected to be in the range of $6 million to $7 million, which includes approximately $1 million in restructuring charges.
LookSmart is increasing its full-year guidance and now expects total revenue to be in the range of $76 million to $81 million, including domestic revenue from MSN of approximately $9 million and revenue from discontinuing international operations of approximately $6 million. This compares to previous revenue guidance of a range of $45 million to $50 million.
Adjusted net loss for 2004 is expected to be $20 million to $22 million, which includes restructuring charges of approximately $5 million. This compares to previous adjusted net loss guidance of $26 million to $30 million, including restructuring charges of $5 million to $8 million.
The Company anticipates negative cash flow over the next several quarters reflecting use of cash for working capital, restructuring and investments, but expects to report a cash position of approximately $60 million at June 30, 2004, and a strong cash position throughout 2004.
Use of Non-GAAP Financial Information
Management believes that Adjusted Net Income/Loss is an appropriate measure of evaluating our operating performance because by excluding the impact of variable stock compensation, which we believe is not indicative of our core operating results, the users of the financial statements are provided with a valuable insight into our operating results. Non-GAAP financial measures should be considered in addition to, and not as a substitute for or superior to, cash flow from operations, net income, or other measures of financial performance prepared in accordance with generally accepted accounting principles.
Conference Call
LookSmart will host a conference call today at 5:00 p.m. ET (9:00 a.m. Australian ET, April 30, 2004) to discuss its financial results. To listen to the call from the U.S., dial 1-800-218-0204; from Australia, dial 1-800-730-220. The call will also be available live by webcast on LookSmart's Investor Relations Web site at http://www.shareholder.com/looksmart/ .
About LookSmart
LookSmart is a leader in commercial search services and a developer of innovative web search solutions. The Company provides consumers with highly relevant search results through a distribution network that includes LookSmart.com and other top portals and ISPs, while delivering targeted sales leads to online businesses. LookSmart is based in San Francisco, California. For more information, visit www.looksmart.com.
IMNR news...
==================
(COMTEX) B: The Immune Response Corporation's NeuroVax(TM) Demonstrates Strong Results in Phase I/II Study in Multiple Sclerosis - Phase I/II Clinical Trial Discontinued
arly After 94 Percent of Patients Show Response - - Results Presented at American Academy of Neurology -
(PRNewswire-FirstCall )
CARLSBAD, Calif., Apr 29, 2004 /PRNewswire-FirstCall via COMTEX/ -- The Immune
Response Corporation (Nasdaq: IMNR), a biopharmaceutical company developing
immune-based therapies (IBT) for HIV and select other diseases, today announced
that its investigational T-cell receptor (TCR) peptide vaccine, NeuroVax(TM),
produced a peptide-specific immune response in 94 percent of the patients
treated in a Phase I/II clinical trial in multiple sclerosis. Results of the
three-armed, randomized trial, which was discontinued early when an interim
analysis revealed the high rate of response, were presented yesterday at the
54th annual meeting of the American Academy of Neurology (AAN) held in San
Francisco, CA.
Earlier clinical research on immunotherapy for multiple sclerosis suggested that
only about half of patients had an immune response to treatment with a single
TCR peptide but that this reaction probably had clinical benefit. NeuroVax(TM)
is composed of a combination of TCR peptides from three families (BV5S2, BV6S5,
and BV13S1) with an adjuvant to improve immune response rates.
"The surprisingly high immunogenic response to NeuroVax(TM), both in the
percentage of patients responding and in the strength of their responses,
validates this new approach to enhancing TCR peptide immunization and suggests
that we may finally be able to more specifically regulate the pathogenic T-cells
thus addressing the underlying causes of the disease," said Dennis N. Bourdette,
MD, Chairman of the Department of Neurology at Oregon Health & Science
University in Portland, Ore., and lead investigator for this study. "Patients
with multiple sclerosis currently have few treatment options. Our research is
continuing to determine if the active immune response to NeuroVax(TM) correlates
with a clinically relevant impact on disease progression."
In the study, 37 patients were randomized to receive either the three TCR
peptides with saline (15 patients), the NeuroVax(TM) combination (16 patients),
or adjuvant alone (6 patients). Patients received monthly injections for 24
weeks, and the induction of TCR peptide-specific T-cell responses was measured
against baseline to gauge immune response. Using an intent-to-treat analysis,
the proportion of patients who were TCR vaccine responders was significantly
greater (p<0.001) in the NeuroVax(TM) group, with 15/16 (94 percent) responding
patients compared with 1/15 (7 percent) for the TCR/saline group and 0/6 for the
adjuvant group.
"With 94 percent of patients showing a disease-specific immune response in this
study, we will continue to pursue development of NeuroVax(TM) in multiple
sclerosis as both a monotherapy and in combination with currently approved
treatments," said John N. Bonfiglio Ph.D., Chief Executive Officer of The Immune
Response Corporation. "NeuroVax(TM) is another example of how immune-based
therapies pioneered by The Immune Response Corporation's co-founder, Dr. Jonas
Salk, may provide a promising new mechanism for fighting difficult diseases.
Together with our product candidates for HIV -- REMUNE(R) and IR103 -- I believe
our pipeline is making the progress necessary to eventually commercialize
products to meet patient needs in two underserved areas."
NeuroVax(TM) was well tolerated over the 24 weeks of therapy. There were no
serious side effects reported, and the only adverse events attributable to
NeuroVax(TM) were injection-site reactions.
Multiple sclerosis is an autoimmune disease in which the immune system, the
body's principal defense against foreign substances such as bacteria, mistakenly
attacks normal tissues of the central nervous system. It afflicts approximately
400,000 people in the United States and more than 2.5 million worldwide.
Specifically, the disease results in the loss of a fatty tissue called myelin
that surrounds and protects nerve fibers, creating scarring (sclerosis) that
interferes with the normal transmission of nerve impulses. This, in turn, leads
to a variety of highly individual and unpredictable neurological symptoms,
ranging from movement and balance problems to vision impairment. It is believed
that a subset of the specific class of white blood cells, CD4+ T-cells, that
normally plays an important role in the immune system, somehow becomes
autoreactive and is principally responsible for the progression of the disease.
TCR peptides have been shown to stimulate regulatory T-cells capable of
suppressing the autoreactive CD4+ T-cells in a certain proportion of patients.
NeuroVax(TM), which combines three TCR peptides with an adjuvant, was designed
to increase the likelihood of this immune reaction.
About The Immune Response Corporation
The Immune Response Corporation (Nasdaq: IMNR) is developing immune-based
therapies (IBT) for HIV and select other diseases. The Company's HIV products
are based on its patented whole-killed virus technology, co-invented by Company
founder, Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE(R), currently
in Phase II, is being developed as a treatment for people with HIV. The Company
has initiated development of a new IBT, IR103, which incorporates a
second-generation immunostimulatory oligonucleotide adjuvant.
The Immune Response Corporation is also developing an IBT for multiple sclerosis
(MS), NeuroVax(TM), which is currently in Phase II and has shown potential
therapeutic value for this difficult-to-treat disease.
Please visit The Immune Response Corporation on the World Wide Web at
www.imnr.com
About OHSU
Oregon Health & Science University, located in Portland, Ore., includes the
schools of dentistry, medicine, nursing and science and engineering; OHSU
Hospital and Doernbecher Children's Hospital; numerous primary care and
specialty clinics; multiple research institutes; and several outreach and
community service units.
This news release contains forward-looking statements. Forward-looking
statements are often signaled by forms of words such as should, could, will,
might, plan, projection, forecast, expect, guidance, potential and developing.
Actual results could vary materially from those expected due to a variety of
risk factors, including whether the Company will continue as a going concern and
successfully raise proceeds from financing activities sufficient to fund
operations and additional clinical trials of REMUNE(R), NeuroVax(TM) or IR103,
the uncertainty of successful completion of any such clinical trials, the fact
that the Company has not succeeded in commercializing any drug, the risk that
REMUNE(R), NeuroVax(TM) or IR103 might not prove to be effective as either a
therapeutic or preventive vaccine, whether future trials will be conducted and
whether the results of such trials will coincide with the results of REMUNE(R),
NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials.
These risks, among others, are set forth in The Immune Response Corporation's
SEC filings including, but not limited to, its Annual Report on Form 10-K for
the year ended December 31, 2003, and any subsequent Quarterly Reports on Form
10-Q. The Company undertakes no obligation to update the results of these
forward-looking statements to reflect events or circumstances after today or to
reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
NeuroVax(TM) is a trademark of The Immune Response Corporation.
MEDIA CONTACT:
Laura Silver, Sam Brown Inc. Corporate Communications
310-551-9940
silver@sambrown.com
INVESTOR RELATIONS CONTACT:
Kathy Waller, Financial Relations Board
312-266-7800
kwaller@financialrelationsboard.com
AT THE COMPANY:
Michael K. Green, Chief Financial Officer
760-431-7080
info@imnr.com
AT OHSU:
Jonathan Modie, media relations coordinator
503-494-8231
modiej@ohsu.edu
SOURCE The Immune Response Corporation
CONTACT: Media, Laura Silver, Corporate Communications of Sam Brown
Inc., +1-310-551-9940, silver@sambrown.com; or Investor Relat
ons, Kathy
Waller of Financial Relations Board, +1-312-266-7800,
kwaller@financialrelationsboard.com, both for The Immune Resp
nse Corporation;
or Michael K. Green, Chief Financial Officer of The Immune Re
ponse
Corporation, +1-760-431-7080, info@imnr.com; or Jonathan Modi
, media
relations coordinator of OHSU, +1-503-494-8231, modiej@ohsu.e
u
URL: http://www.imnr.com
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
-0-
KEYWORD: California
Oregon
INDUSTRY KEYWORD: HEA
MTC
BIO
SUBJECT CODE: SVY
*** end of story ***
KNOS news...
===================
(COMTEX) B: Kronos Receives Third U.S. Patent ( PRNewswire-FirstCall )
BELMONT, Mass., Apr 29, 2004 /PRNewswire-FirstCall via COMTEX/ -- Kronos
Advanced Technologies, Inc. (OTC Bulletin Board: KNOS) announced today that
Kronos Air Technologies, Inc., a wholly owned subsidiary of Kronos Advanced
Technologies, has received notification from the United States Patent and
Trademark Office that Kronos Air's patent application entitled Electrostatic
Fluid Accelerator for and a Method of Controlling Fluid Flow has been examined
and issued as a U.S. patent.
This patent represents an innovative solution to using an electrostatic fluid
accelerator to produce commercially useful air flow rates. Kronos' Chief
Technology Officer, Dr. Igor Krichtafovitch, and Senior Research and Product
Development Leader, Dr. Vladimir Gorobets, are the inventors of this proprietary
technology.
The Electrostatic Fluid Accelerator for and a Method of Controlling Fluid Flow
patent is the third in a series of patent applications pending with the U.S.
Patent and Trademark Office addressing various aspects of the Kronos technology.
A number of corresponding applications have been filed and are pending outside
of the United States. This latest patent will provide intellectual property
protection for key aspects of the Kronos' technology until 2021.
In addition to the Electrostatic Fluid Accelerator, Method of and Apparatus for
Electrostatic Fluid Acceleration Control of a Fluid Flow, and Electrostatic
Fluid Accelerator for and a Method of Controlling Fluid Flow patents, a number
of additional patent applications have been filed for, among other things, the
control and management of electrostatic fluid acceleration. These additional
patent applications are either being examined or are awaiting examination by the
Patent Office.
Other Developments
Kronos Air will be presenting at the 2004 U.S. Navy Opportunity Forum -
Transitioning Technology to the Fleet on May 3 - 4, 2004 in Reston, Virginia. In
conjunction with Kronos Air's presentation, management will be demonstrating
commercial and military air movement and filtration products developed using the
Company's proprietary technology. The objective of the Forum is to provide an
effective way for defense program managers, acquisition officers, prime
contractors, and other private sector corporations and investors to preview
Navy-funded technologies developed by small businesses. Conference attendees can
preview technologies and explore both partnering and investment opportunities
with firms from around the country. The 2004 Forum will showcase ninety firms
that have each received over $750,000 of Navy funding through the Small Business
Innovation Research (SBIR) program during the past two years. More information
on the Forum is available at http://www.dawnbreaker.com/forums/navy/. A copy of
Kronos' Navy Forum presentation will be made available online at
http://www.kronosati.com/solmilitary.html.
About Kronos Advanced Technologies, Inc.
Through its wholly owned subsidiary, Kronos Air Technologies, Inc., Kronos
Advanced Technologies focuses on the development and commercialization of a new,
proprietary air movement and purification technology. Kronos(TM) technology
utilizes state-of-the-art high voltage electronics and electrodes to create an
efficient but simple electrical device. As a result of this combined technology,
the Kronos(TM) air movement and purification device can move and clean air
without any moving parts. The device is versatile, energy and cost-efficient,
and exhibits multiple design attributes, creating a broad range of applications.
More information about Kronos Advanced Technologies is available at
www.kronosati.com.
Contact:
Kronos Advanced Technologies: Daniel R. Dwight, CEO, 617-993-9965,
email: investors@kronosati.com.
With the exception of historical information contained in this press release,
this press release includes forward-looking statements and comments. Such
statements are necessarily subject to risks and uncertainties, some of which are
significant in scope and nature beyond the Company's control. Forward-looking
statements, by their nature, involve substantial risks and uncertainties. As a
result, actual results may differ materially depending on many factors,
including those described above. The Company cautions that historical results
are not necessarily indicative of the Company's future performance. Other risks
are summarized under the caption "Certain Business Risk Factors" in the
Company's Annual Report on Form 10-KSB for the year ended June 30, 2003 as filed
with the Securities and Exchange Commission.
SOURCE Kronos Advanced Technologies, Inc.
CONTACT: Daniel R. Dwight, CEO of Kronos Advanced Technologies, +1-617
993-9965, investors@kronosati.com
URL: http://www.kronosati.com
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
-0-
KEYWORD: Massachusetts
INDUSTRY KEYWORD: ENV
*** end of story ***
AMUT news...
=====================
(BSNS WIRE) American Multiplexer Corp. Announces that eFotoXpress Software has Met All Engineering Requirements by the Department of Defense
High-Tech Writers / Business Editors
SUNNYVALE, Calif.--(BUSINESS WIRE)--AMUT--
American Multiplexer Corp. (OTC:AMUT) announced today
that the Department of Defense has reviewed and tested eFotoXpress
software. eFotoXpress has met all engineering requirements established
by the Department of Defense. The Company expects that its software
product will now be used by the Marine Corp at about 500 seats. The
product is now in the procurement process. The company expects to
receive a Purchase Order from the Department of Defense shortly.
Edward Tan, President and CEO said, "This is a new critical
strategic alliance for American Multiplexer. This will be our first
sale to a Government Agency which provides a significant expansion of
our customer base. We are very proud that eFotoXpress has been
accepted by the DOD."
About eFotoXpress
eFotoXpress is a software utility that uses wavelet compression
technology and the new JPEG2000 standard to easily compress very large
images so that they may be sent by e-mail without any loss in quality.
eFotoXpress is the first product that uses the new JPEG2000 standard
so that compressed images may be sent via e-mail. New eFotoXpress
features include talking slide show and text images and choices of
print sizes. A large 80m image can easily be compressed to 80K without
loss of quality.
The eFotoXpress product is an easy-to-use photo utility that
compresses images with highest possible efficiency. The digital images
can be sent to many different recipients with one click of button.
This product is designed to compress any high-resolution JPEG images
from different digital cameras, scanners and camcorders. eFotoXpress
works with many email utilities, such as Microsoft Outlook, Yahoo, and
Hotmail. This utility will allow digital camera users to send more
digital pictures over the Internet at a greater speed through the use
of highly integrated compression technologies.
About AMC
Located in Sunnyvale, California, AMC (a publicly traded company)
is a major leader in developing JPEG2000 consumer products. The
company continues to invest its resources in the compression
technology that addresses the digital camera market.
Visit us at www.amux.com
Safe Harbor Statement
This announcement contains forward-looking statements. These
statements are based on current plans, estimates and projections and
contain risks. Do not place reliance on them. Other factors can change
these forward-looking statements and may lead to potential risks and
total losses. Consult your investment advisors before making any
investment in the stocks. The company is not responsible for any
inaccuracies.
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: RETAIL SOFTWARE E-COMMERCE INTERNET COMPUTERS/ELECTRONICS PROD
CT
SOURCE: American Multiplexer Corp.
CONTACT INFORMATION:
AMC
Edward Tan, 408-730-8200 ext. 100
edward.tan@amux.com
*** end of story ***
POSO news...
====================
(COMTEX) B: ProsoftTraining Regains Nasdaq Compliance
B: ProsoftTraining Regains Nasdaq Compliance
PHOENIX, Apr 29, 2004 (BUSINESS WIRE) -- ProsoftTraining (Nasdaq:POSO) today
announced that the Nasdaq SmallCap Market has determined that Prosoft has
regained compliance with Marketplace Rule 4450(a)(5) concerning the bid price
requirement for continued listing. In its communication to the Company, Nasdaq
stated that "the closing bid price of the Company's common stock has been at or
greater than $1.00 for at least 10 consecutive trading days. Accordingly, the
Company has regained compliance with the Rule and this matter is now closed."
"We are very pleased to regain compliance with the Marketplace Rule and thus
remove the lengthy uncertainty that has existed concerning the listing status of
our common stock," stated Robert Gwin, chairman and CEO of Prosoft.
About ProsoftTraining
ProsoftTraining (Nasdaq:POSO) offers content and certifications to enable
individuals to develop and validate critical Information and Communications
Technology (ICT) workforce skills. Prosoft is a leader in the workforce
development arena, working with state and local governments and school districts
to provide ICT education solutions for high school and community college
students. Prosoft has created and distributes a complete library of classroom
and e-learning courses. Prosoft distributes its content through its ComputerPREP
division to individuals, schools, colleges, commercial training centers and
corporations worldwide. Prosoft owns the CIW job-role certification program for
Internet technologies and the CCNT (Certified in Convergent Network
Technologies) certification, and developed and manages the CTP (Convergence
Technologies Professional) vendor-neutral certification for telecommunications.
To learn more, visit www.ProsoftTraining.com, www.ComputerPREP.com,
www.CIWcertified.com and www.CTPcertified.com.
Except for historical information contained herein, the matters discussed in
this press release are statements of a forward-looking nature that are subject
to certain risks and uncertainties that could cause actual results to differ
materially from those projected. Such risks and uncertainties include, without
limitation, Prosoft's ability to maintain its Nasdaq SmallCap Market listing in
the future, and the other risks and uncertainties outlined in the Company's
filings with the Securities and Exchange Commission, including, but not limited
to, the Company's Annual Report on Form 10-K/A. The Company undertakes no
obligation to update this forward-looking information.
SOURCE: ProsoftTraining
CONTACT: ProsoftTraining
Investor Relations, 602-794-4101
investors@prosofttraining.com
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved.
-0-
KEYWORD: ARIZONA
INDUSTRY KEYWORD: GOVERNMENT
SOFTWARE
HARDWARE
COMPUTERS/ELECTRONICS
EDUCATION
*** end of story ***